ZymoGenetics, Inc. engages in the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases in the areas of hemostasis, inflammatory and autoimmune diseases, cancer, and viral infections. Its preclinical stage internal products include IL-31, for the treatment of atopic dermatitis and inflammatory diseases. The company’s phase II internal candidates comprise atacicept for the treatment of systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis; and IL-21 for the treatment of metastatic melanoma/metastatic renal cell carcinoma. Its phase I out-licensed candidates consist of rFactor XIII for congenital factor XIII deficiency and cardiac surgery. ZymoGenetics also develops rhThrombin, a phase III product, for the treatment of general surgical hemostat and line extensions; and PEG-Interferon lambda, which is in phase I clinical trial for the treatment of hepatitis C virus infection. In addition, it provides six out-licensed products, which include Novolin and NovoRapid, which are used in the treatment of diabetes; NovoSeven for use in the treatment of hemophilia; Regranex for wound healing; GEM 21S for the treatment of periodontal defects; GlucaGen for hypoglycemia and gastrointestinal motility inhibition; and Cleactor, which is used for the treatment of myocardial infarction. ZymoGenetics has a strategic alliance with Merck Serono S.A for the research, development, and commercialization of novel protein and antibody therapeutics derived from the company’s proprietary portfolio of genes and proteins; and a collaboration with Bayer HealthCare for the development and commercialization of recombinant human thrombin. The company was founded in 1981 and is headquartered in Seattle, Washington.